NZ752443A - Lasofoxifene treatment of er+ breast cancer - Google Patents

Lasofoxifene treatment of er+ breast cancer

Info

Publication number
NZ752443A
NZ752443A NZ752443A NZ75244317A NZ752443A NZ 752443 A NZ752443 A NZ 752443A NZ 752443 A NZ752443 A NZ 752443A NZ 75244317 A NZ75244317 A NZ 75244317A NZ 752443 A NZ752443 A NZ 752443A
Authority
NZ
New Zealand
Prior art keywords
breast cancer
lasofoxifene
treatment
estrogen receptor
endocrine
Prior art date
Application number
NZ752443A
Other languages
English (en)
Inventor
Kaitlyn Andreano
Ching-Yi Chang
Donald Mcdonnell
Stephanie Gaillard
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Priority to NZ793063A priority Critical patent/NZ793063A/en
Publication of NZ752443A publication Critical patent/NZ752443A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
NZ752443A 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer NZ752443A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ793063A NZ793063A (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US201762502299P 2017-05-05 2017-05-05
PCT/US2017/055970 WO2018093484A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Publications (1)

Publication Number Publication Date
NZ752443A true NZ752443A (en) 2022-11-25

Family

ID=60186386

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ752443A NZ752443A (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer
NZ793063A NZ793063A (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ793063A NZ793063A (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Country Status (20)

Country Link
US (8) US20190231718A1 (enExample)
EP (2) EP3525774B1 (enExample)
JP (4) JP6892151B2 (enExample)
KR (5) KR20240007720A (enExample)
CN (3) CN112353796A (enExample)
AU (3) AU2017360365B2 (enExample)
BR (1) BR112019007254A2 (enExample)
CA (1) CA3040266A1 (enExample)
DK (1) DK3525774T3 (enExample)
ES (1) ES2909576T3 (enExample)
IL (2) IL284875B (enExample)
MX (2) MX387856B (enExample)
NZ (2) NZ752443A (enExample)
PL (1) PL3525774T3 (enExample)
PT (1) PT3525774T (enExample)
RU (1) RU2019114079A (enExample)
SG (2) SG11201903236SA (enExample)
TW (4) TWI790672B (enExample)
WO (2) WO2018093484A1 (enExample)
ZA (1) ZA201902454B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974983B2 (en) 2018-04-10 2024-05-07 Duke University Lasofoxifene treatment of breast cancer
US11980597B2 (en) 2016-10-11 2024-05-14 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
TW202410890A (zh) * 2022-05-25 2024-03-16 美商神莫尼克斯製藥公司 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療
WO2025075631A1 (en) 2023-10-06 2025-04-10 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of endocrine therapy resistant er+ cancer
WO2025099482A1 (en) * 2023-11-06 2025-05-15 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Synergistic loratadine-raloxifene-sorafenib compositions for the treatment of hepatic cancer
WO2025122504A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025165887A1 (en) * 2024-01-30 2025-08-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of er+ cancers with constitutively active esr1 mutations
CN119842900A (zh) * 2025-01-17 2025-04-18 厦门飞朔生物技术有限公司 一种可用于乳腺癌内分泌耐药治疗指导的人esr1基因突变检测试剂盒

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
WO1999065498A1 (en) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Agents for relieving side effects of adrenal cortex hormone
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
AU2991301A (en) 2000-01-28 2001-08-07 Endorecherche Inc. Selective estrogen receptor modulators in combination with estrogens
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
CN100448487C (zh) 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
WO2002056903A2 (en) 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
BR0308758A (pt) 2002-03-28 2004-12-28 Pfizer Prod Inc Lasofoxifeno purificado e método para purificação de lasofoxifeno racêmico por recristalização
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
MX368189B (es) 2004-10-20 2019-09-23 Endorecherche Inc Precursores esteroides sexuales solos o en combinación con un modulador receptor de estrógeno selectivo y/o con estrógenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevención y tratamiento de sequedad vaginal y disfunción sexual en mujeres post-menopáusicas.
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
MY161598A (en) 2009-01-30 2017-04-28 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
US9351964B2 (en) * 2009-05-27 2016-05-31 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
EP2606130B1 (en) 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
JP2014508782A (ja) 2011-03-11 2014-04-10 メリマック ファーマシューティカルズ インコーポレーティッド ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用
EP2709661A4 (en) 2011-05-18 2015-01-28 Merck Sharp & Dohme COMBINATIONS OF THERAPEUTIC ANTI-IGF1R
WO2013056178A2 (en) * 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
WO2015136017A1 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN104208069A (zh) 2014-05-08 2014-12-17 上海市计划生育科学研究所 双炔失碳酯组合物和疾病治疗方法
EP3215137A1 (en) 2014-11-07 2017-09-13 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
US20180049999A1 (en) 2015-04-14 2018-02-22 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Duke University tratamento lasofoxifeno de câncer de mama er+
US20190231743A1 (en) 2016-10-11 2019-08-01 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
US10624874B2 (en) 2017-01-10 2020-04-21 Zhejiang Jiachi Development Pharmaceuticals Ltd Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
WO2019199891A1 (en) * 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN113490850B (zh) * 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN118369116A (zh) 2021-10-05 2024-07-19 杜克大学 包含肿瘤免疫的小分子调节物的组合物及其使用方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
TW202410890A (zh) 2022-05-25 2024-03-16 美商神莫尼克斯製藥公司 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980597B2 (en) 2016-10-11 2024-05-14 Duke University Lasofoxifene treatment of breast cancer
US12414924B2 (en) 2016-10-11 2025-09-16 Duke University Lasofoxifene treatment of breast cancer
US11974983B2 (en) 2018-04-10 2024-05-07 Duke University Lasofoxifene treatment of breast cancer
US12023321B2 (en) 2021-11-18 2024-07-02 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+cancer
US12433866B2 (en) 2021-11-18 2025-10-07 Sermonix Pharmaceuticals, Inc. Lasofoxifene treatment of aromatase-resistant ER+ cancer

Also Published As

Publication number Publication date
JP2019529581A (ja) 2019-10-17
US11980597B2 (en) 2024-05-14
WO2018093484A1 (en) 2018-05-24
TWI836808B (zh) 2024-03-21
PT3525774T (pt) 2022-03-30
KR102285453B1 (ko) 2021-08-05
KR20210096316A (ko) 2021-08-04
BR112019007254A2 (pt) 2019-07-02
CN112353796A (zh) 2021-02-12
IL265938A (en) 2019-05-30
US20190231718A1 (en) 2019-08-01
US20210361596A1 (en) 2021-11-25
EP4035662A1 (en) 2022-08-03
US20180221335A1 (en) 2018-08-09
PL3525774T3 (pl) 2022-04-25
CN110099680B (zh) 2021-02-05
MX387856B (es) 2025-03-19
KR102462433B1 (ko) 2022-11-03
ZA201902454B (en) 2022-09-28
TWI896001B (zh) 2025-09-01
SG11201903236SA (en) 2019-05-30
TWI790672B (zh) 2023-01-21
MX2021013911A (es) 2022-01-18
US20190151286A1 (en) 2019-05-23
NZ793063A (en) 2025-09-26
TWI729227B (zh) 2021-06-01
KR20190092377A (ko) 2019-08-07
IL284875B (en) 2022-07-01
EP3525774B1 (en) 2021-12-29
EP3525774A1 (en) 2019-08-21
JP6892151B2 (ja) 2021-06-23
RU2019114079A (ru) 2020-11-13
TW202137980A (zh) 2021-10-16
JP2024026527A (ja) 2024-02-28
KR20230042390A (ko) 2023-03-28
TW202446367A (zh) 2024-12-01
ES2909576T3 (es) 2022-05-09
JP7418052B2 (ja) 2024-01-19
AU2025200327A1 (en) 2025-02-06
JP7247241B2 (ja) 2023-03-28
TW202313005A (zh) 2023-04-01
CA3040266A1 (en) 2018-05-24
TW201817422A (zh) 2018-05-16
JP7774896B2 (ja) 2025-11-25
KR102531354B1 (ko) 2023-05-11
CN112933082A (zh) 2021-06-11
CN110099680A (zh) 2019-08-06
IL265938B (en) 2021-08-31
KR20240007720A (ko) 2024-01-16
SG10201913951YA (en) 2020-03-30
KR20220151017A (ko) 2022-11-11
MX2019004184A (es) 2019-09-27
US20250064757A1 (en) 2025-02-27
RU2019114079A3 (enExample) 2021-07-23
WO2018071440A1 (en) 2018-04-19
DK3525774T3 (da) 2022-03-14
AU2017360365A1 (en) 2019-05-02
JP2021073316A (ja) 2021-05-13
AU2022246480A1 (en) 2022-12-08
US10905659B2 (en) 2021-02-02
JP2023033415A (ja) 2023-03-10
US20240366534A1 (en) 2024-11-07
US12414924B2 (en) 2025-09-16
US10258604B2 (en) 2019-04-16
AU2017360365B2 (en) 2022-08-04
US20230233490A1 (en) 2023-07-27
IL284875A (en) 2021-08-31
US20180098963A1 (en) 2018-04-12
KR102623130B1 (ko) 2024-01-10
AU2022246480B2 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
NZ752443A (en) Lasofoxifene treatment of er+ breast cancer
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
SG10201806656UA (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
MX2016011698A (es) Metodos y composiciones para modular mutantes de receptor de estrogeno.
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP4589014A3 (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
PH12016502354A1 (en) Pharmaceutical composition
MY186977A (en) Tetrasubstituted alkene compounds and their use
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
IL273782A (en) Compositions of cells and bacteria for the treatment of colon cancer and methods for evaluating prognosis for these patients
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
MX388166B (es) Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos
IL276748A (en) Methods for the detection and treatment of prostate cancer
GB201806064D0 (en) Improved Classification And Prognosis Of Prostate Cancer
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
SG11202106295WA (en) Compositions and methods for cancer therapy
SG11202107488PA (en) Methods of treating breast cancer with tucatinib
IL280830A (en) Bracelets for use in cancer treatment methods
PH12018502360A1 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer
NZ742470A (en) Combination therapy for cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 OCT 2026 BY CHRIS REVIE

Effective date: 20250917